Table 2 Scoring methodology for the available information

Stage I screening

Clinical potential

Actively considered for clinical development with at least solid preclinical data

NA

Mainly in vitro data and < 5 studies showing preclinical evidence

Stage II screening

Relevance to immunotherapy

Directly activate immune system or known to have significant indirect effects on immune system

NA

Not known to directly or indirectly activate immune system

Stage III screening

Relevance of Indication

> 3 indications in solid tumors including NSCLC in clinical development

At least 3 indications in clinical development

< 3 indications in clinical development or heme indications only

Knowledge of MoA

Biology is clearly established with details of interactions at cellular and molecular levels

Biology is not clearly established with only few details on molecular interactions

Biology not known

Effects on immune response

Directly activate effector immune cells such as CD8 T-cells or NK cells

Act by stimulating the proliferation of immune cells or increasing the infiltration of immune cells into tumors

Indirectly activate immune system through antigen release

Stage IV screening

Availability of data

Efficacy and safety data validated in multiple clinical studies

NA

Limited clinical or only preclinical efficacy and safety data

Scoring of clinical data

Clinical efficacy data

Data available from combination with PD-1/PD-L1 blockers in solid tumors; Data from monotherapy in solid tumors and combination with chemotherapy in solid tumors

Only data from monotherapy; or only combination therapy in solid tumors is available

Only data from heme tumors and/or preclinical data is available

Other information summarized (not scored)

Setting

Adjuvant +/- or Adv/Metastatic 1-2 L or Adv/Metastatic 3-4 L+

Combination studies

Combination studies with CIT or targeted therapy or with standard of care (e.g. chemotherapy)

Efficacy

Molecule/target active by itself in multiple indications or single indication or only in combination

Safety

Whether AEs manageable and reversible with treatment cessation or require additional treatment for reversal or require hospitalization and aggressive treatment for reversal

Grade 3 or more incidence

Phase

Phase 1/2/3/4 or pre-clinical

Time to read out

< 1 years or 1–3 years or > 3 years